<DOC>
	<DOCNO>NCT00820885</DOCNO>
	<brief_summary>The primary objective study study safety tolerability teduglutide follow possibly twice daily subcutaneous injection eight consecutive day healthy subject . A secondary objective study pharmacokinetics teduglutide follow possibly twice daily injection eight consecutive day healthy subject .</brief_summary>
	<brief_title>A Double-Blind Multi-Dose Tolerability Pharmacokinetic Study Teduglutide</brief_title>
	<detailed_description>Healthy subject enrol screen determined qualify . The subject randomize either placebo dose teduglutide outline protocol 1:3 ratio . They inject investigational product eight consecutive day , measurement take include safety .</detailed_description>
	<criteria>Men woman 20 55 year age BMI 1835 inclusive Able understand sign inform consent form Willing able confine clinical research center 8.5 day Women postmenopausal , surgically sterilize , agree use effective form birth control Women child bear potential negative pregnancy test screen checkin Medically healthy normal clinical result ECG/lab profile screen checkin Exclusion Criteria Donated 1 pint blood/blood product within 56 day prior study receive plasma within 7 day prior study Pregnancy become pregnant Participated another investigational trial 30 day prior Physical examination/medical history indicate clinical condition concurrent illness unsuitable study History/presence clincally significant disease body system History/evidence congenital honhemolytic hyperbilirubinemia History/evidence gall stone disease , stomach intestinal surgery History/evidence colorectal cancer History/evidence GI disease , e.g. , malabsorption , Crohn 's Disease , etc . History/evidence skin rash dermatitis Taking prescription counter medication ( exception oral contraception ) 7 day precede confinement clinical unit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>